^(131)I-间碘苄胍治疗94例恶性嗜铬细胞瘤转移灶25年随访的疗效评价  

Efficacy evaluation of 25-year follow-up in 94 cases of malignant pheochromocytoma with metastases treated by ^(131)I-meta-iodo benzyl guanidine

作　　者：罗琼[1] 罗全勇[1] 朱瑞森[1] 袁志斌[1] 丁颖[1] 

机构地区：[1]上海交通大学附属第六人民医院核医学科,上海200233

出　　处：《中国医药导报》2011年第32期29-30,90,共3页China Medical Herald

摘　　要：目的:观察并总结131I-间碘苄胍(131I-MIBG)治疗恶性嗜铬细胞瘤转移灶的临床疗效。方法:我院1986年1月～2010年1月共收治94例恶性嗜铬细胞瘤转移的患者。按转移瘤大小将其分为三组,三组患者均每隔1～2个月静滴131I-MIBG 80～100 mCi,如果肿瘤组织接受辐照剂量达1 000 cGy/g以上,则每隔3～6个月治疗1次,每次80～100 mCi。结果:大部分患者症状消失,治疗总有效率达73.4%。131I-MIBG对于中小体积的肿瘤的治疗效果较好,与大体积肿瘤疗效比较,差异有统计学意义(χ2=143.19,P<0.05)。每克肿瘤组织接受辐照的剂量与其原始大小有密切关系。每克肿瘤组织接收剂量达1 500～2 000 cGy时,肿瘤可消失或明显缩小。结论:131I-MIBG对恶性嗜铬细胞瘤转移灶具有较好的疗效且副反应较小,不能行手术切除者可首选此方法治疗。Objective： To observe and summarize the therapeutic effects of 13q-MIBG in treatment of malignant pheochromocytoma with metastases. Methods： 94 patients of malignant pheochromocytoma with metastases who were treated from January 1986 to January 2010 in our hospital were classified into 3 groups according to their tumor size. Intravenous infusion of 131I-MIBG 80-100 mCi was given every 1-2 months, or every 3-6 months if the absorption dose per gram of tumor was above 1 000 cGy. Results： Clinical symptoms disappeared in most patients after treatment, and the total effective rate was 73.4%. The effects in the small and medium volume groups were better than those in the large volume group （χ2= 143.19, P〈0.05）. The absorption dose of tumor was closely related to its volume. When the absorption dose of tumor attained 1 500-2 000 cGy/g, the tumor was smaller or disappear obviously. Conclusion： 131I-MIBG has certain therapeutic effectiveness and low side effects in treatment of malignant pheochromocytoma with metastases. Thus, treatment with 131I- MIBG should be the first selection for masses unable surgical resection.

关 键 词：恶性嗜铬细胞瘤 131I-间碘苄胍 副作用 辐照剂量 

分 类 号：R817.8[医药卫生—影像医学与核医学]